Congleton Jon 4
4 · Mineralys Therapeutics, Inc. · Filed Jun 30, 2026
Research Summary
AI-generated summary of this filing
Mineralys (MLYS) CEO Jon Congleton Sells Shares
What Happened
Jon Congleton, CEO of Mineralys Therapeutics (MLYS), sold a total of 75,000 shares on June 30, 2026 in two open-market transactions. He disposed of 58,000 shares at a weighted-average price of $25.94 for proceeds of $1,504,706 (range $25.56–$26.50) and 17,000 shares at a weighted-average price of $26.82 for proceeds of $455,896 (range $26.645–$26.82), for combined proceeds of approximately $1,960,602. These were sales (S), not purchases.
Key Details
- Transaction date: 2026-06-30 (filed 2026-06-30) — no late filing indicated in the provided data.
- Sales: 58,000 shares @ $25.94 (weighted avg; range $25.5600–$26.5000) and 17,000 shares @ $26.82 (weighted avg; range $26.6450–$26.8200).
- Total shares sold: 75,000; total proceeds ≈ $1,960,602.
- Shares owned after transaction: not disclosed in the supplied filing excerpt.
- Notable footnotes: (F1) Sales were effected under a Rule 10b5‑1 trading plan adopted Dec 30, 2025. (F2/F3) Reported prices are weighted averages covering multiple trades; the reporting person will provide per-trade breakdowns on request.
Context
These are open-market sales executed under a pre-established 10b5‑1 plan, which often indicate scheduled, rule-compliant disposals rather than opportunistic timing by insiders. Sales are common and do not by themselves indicate a change in company fundamentals; purchases typically attract more attention as a bullish signal.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-06-30$25.94/sh−58,000$1,504,706→ 631,321 total - Sale
Common Stock
[F1][F3]2026-06-30$26.82/sh−17,000$455,896→ 614,321 total
Footnotes (3)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.5600 to $26.5000. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.6450 to $26.8200. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.